Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Conditions

Myasthenia Gravis 5

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Has results × rozanolixizumab × Clear all
NCT03971422 2025-12-24

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
200 enrolled 20 charts

Myasthenia Gravis

NCT05681715 2025-11-06

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

UCB Pharma

Phase 3 Completed
62 enrolled 11 charts

Myasthenia Gravis

NCT04650854 2025-04-18

A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
165 enrolled 21 charts

Myasthenia Gravis

NCT04124965 2023-09-05

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
71 enrolled 15 charts

Myasthenia Gravis

NCT03052751 2021-08-03

Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

UCB Pharma

Phase 2 Completed
43 enrolled 12 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡